{"id":"NCT00086580","sponsor":"Genzyme, a Sanofi Company","briefTitle":"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients","officialTitle":"A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2004-07-08","resultsPosted":"2011-08-11","lastUpdate":"2014-03-13"},"enrollment":335,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["B-Cell Chronic Lymphocytic Leukemia"],"interventions":[{"type":"BIOLOGICAL","name":"FluCAM [Fludara + Campath]","otherNames":["alemtuzumab","fludarabine phosphate","Fludara","Campath"]},{"type":"BIOLOGICAL","name":"fludarabine phosphate","otherNames":["Fludara"]}],"arms":[{"label":"Combination Arm (FluCAM)","type":"EXPERIMENTAL"},{"label":"Fludarabine Alone","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 3, prospective, multicenter, open-label, randomized, controlled study to evaluate and compare the efficacy and safety of fludarabine plus alemtuzumab versus fludarabine alone as second-line therapy for patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). Patients who meet all eligibility criteria and sign the informed consent document may be entered on the study.","primaryOutcome":{"measure":"Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment","timeFrame":"Up to 6 years","effectByArm":[{"arm":"Combination Arm (FluCAM)","deltaMin":23.65,"sd":null},{"arm":"Fludarabine Alone","deltaMin":16.48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":48,"countries":["United States","Austria","Bulgaria","Canada","Croatia","France","Germany","Greece","Italy","Poland","Portugal","Romania","Russia","Sweden","Ukraine"]},"refs":{"pmids":["21992852"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":54,"n":164},"commonTop":["Neutropenia","Pyrexia","Leukopenia","Thrombocytopenia","Anaemia"]}}